{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-126322","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.070935+00:00","generated_at":"2026-05-15T08:51:50.973875+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inhibikase reports FY2025 net loss $48.3M; advances IKT-001 into Phase 3 PAH trial","bullets":["Net loss of $48.3M ($0.49/share) for FY2025 vs $27.5M ($1.16/share) in FY2024.","Cash and marketable securities $178.8M at Dec 31, 2025, up from $97.5M.","Closed $115M public offering of common stock and pre-funded warrants in Nov 2025.","Initiated global adaptive Phase 3 IMPROVE-PAH study for IKT-001 in PAH; Part A (140 pts, PVR) then Part B (346 pts, 6MWD).","Regulatory submissions in >20 countries; FAST-EU acceptance for accelerated trial approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-126322","json":"https://secwatch.observer/filing/0001193125-26-126322.json","markdown":"https://secwatch.observer/filing/0001193125-26-126322.md","text":"https://secwatch.observer/filing/0001193125-26-126322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526126322/0001193125-26-126322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526126322/d119328d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:51:50.973875+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"021b2c4f105a4a7b61474359603219d5400e2b20","claim":"Inhibikase Therapeutics, Inc. reported year ended December 31, 2025 results: net income $48.3 million, EPS $0.49 per share.","evidence_excerpt":"Net loss for the year ended December 31, 2025, was $48.3 million, or $0.49 per share, compared to a net loss of $27.5 million, or $1.16 per share in the year ended December 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526126322/0001193125-26-126322-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Net income","value":"$48.3 million"},{"label":"EPS","value":"$0.49 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}